Liquidia Corporation Common Stock (LQDA) — Analysis Summary
Liquidia Corporation Common Stock (LQDA) has a market cap of $5.85B with year-over-year revenue growth of +1031.2%. Net margin stands at -43.5%. The stock trades at a P/E ratio of 42.2.
Key Takeaways
- Revenue changed +1031.2% year-over-year
- Net margin of -43.5%
- P/E ratio of 42.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LQDA posted revenue growth of +1031.2% and trades at a P/E of 42.2.
Liquidia Corporation Common Stock (LQDA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (37.4%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
216
Headquarters
MORRISVILLE, NC
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.